An Extention Study of Safety of Canakinumab in Japanese Patients With Periodic Fever Syndromes

Summary

The primary objective of this study was to evaluate safety and tolerability of ACZ885 in this extension study. This extension study offered the opportunity for participants who completed Epoch 4 of the preceding CACZ885N2301 (NCT02059291) study to continue to be treated with ACZ885 until approval in Japan of the drug in Periodic Fever Syndromes or until development of ACZ885 in Periodic Fever Syndromes was suspended.

Timeline

Start

2016-10-03

Primary completion

2017-01-27

Completion

2017-01-27

Drugs

Indications